Insider Sales Surge at Ligand Pharmaceuticals Amid $23 Million Eye‑Drop Deal Boosts Investor Optimism
Zimmermann Martine sells 115 Ligand shares—insider selling amid a 76% rally—yet the company’s new $23 M royalty deal with Santen may offset dilution and boost long‑term growth.
3 minutes to read